Epinephrine Autoinjector Market Highlights the Impact of COVID-19 2020-2024 | Increasing Prevalence of Allergies to boost Market Growth | Technavio

Technavio has been monitoring the epinephrine autoinjector market and it is poised to grow by USD 762.51 million during 2020-2024, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200807005318/en/

Technavio has announced its latest market research report titled Global Epinephrine Autoinjector Market 2020-2024 (Graphic: Business Wire)

Technavio has announced its latest market research report titled Global Epinephrine Autoinjector Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

  • Which is the leading segment based on dosage in the market?
  • The 0.30 gm dosage segment is expected to be the leading segment based on dosage in the global market during the forecast period.
  • What is the major trend for market?
  • Technological advances are a major growth factor for the market.
  • At what rate is the market projected to grow?
  • Growing at a CAGR of over 7%, the incremental growth of the market is anticipated to be USD 762.51 million.
  • Who are the top players in the market?
  • Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants.
  • What are the key market drivers and challenges?
  • Increasing prevalence of allergies and technological advances are the major factors driving the market. However, product recalls and regulatory issues will restrain market growth.

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. The increasing prevalence of allergies will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in fast-growing segments, while maintaining their position in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Epinephrine Autoinjector Market 2020-2024: Segmentation

Epinephrine Autoinjector Market is segmented as below:

  • End-user
    • Hospitals
    • Clinics
    • Individuals
  • Market Landscape
    • 0.30 Gm
    • 0.15 Gm
    • 0.50 Gm
  • Geography
    • North America
    • Europe
    • Asia
    • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43297

Epinephrine Autoinjector Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The epinephrine autoinjector market report covers the following areas:

  • Epinephrine Autoinjector Market Size
  • Epinephrine Autoinjector Market Trends
  • Epinephrine Autoinjector Market Analysis

This study identifies technological advances as one of the prime reasons driving the epinephrine autoinjector market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Epinephrine Autoinjector Market 2020-2024: Key Highlights

  • CAGR of the market during the forecast period 2020-2024
  • Detailed information on factors that will assist epinephrine autoinjector market growth during the next five years
  • Estimation of the epinephrine autoinjector market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the epinephrine autoinjector market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of epinephrine autoinjector market vendors

Table of Contents:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Force Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Dosage

  • Market segments
  • Comparison by Dosage
  • 0.30gm - Market size and forecast 2019-2024
  • 0.15gm - Market size and forecast 2019-2024
  • 0.50gm - Market size and forecast 2019-2024
  • Market opportunity by Dosage

Market Segmentation by Age Group

  • Market segmentation by Age Group

Market Segmentation by End-user

  • Hospitals and clinics
  • Individuals

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver – demand-led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Adamis Pharmaceuticals Corp.
  • ALK-Abello AS
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • kaleo Inc.
  • Lincoln Medical Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts:

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.